Ospemifene: First global approval

Drugs

Volumn 73, Issue 6, 2013, Pages 605-612

  Elkinson, Shelley ^a   Yang, Lily P H ^b  

^a Adis RandD Insight 41 Centorian Drive ^*  (New Zealand)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; OSPEMIFENE; PLACEBO; RALOXIFENE; RIFAMPICIN; WARFARIN;

AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BRAIN HEMORRHAGE; BREAST TENDERNESS; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHIDROSIS; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MELANCHOLIA; MENOPAUSAL SYNDROME; MUSCLE SPASM; MYALGIA; PALLOR; PARESTHESIA; PELVIC ORGAN PROLAPSE; PETECHIA; POSTMENOPAUSE; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SINUSITIS; SKIN PRURITUS; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA EPITHELIUM; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; WEAKNESS;

ANIMALS; ATROPHY; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; DYSPAREUNIA; FEMALE; HUMANS; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VAGINAL DISEASES; VULVA;

EID: 84878307577     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0046-y     Document Type: Article

References (40)

1. O Tan K Bradshaw BR Carr 2012 Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review Menopause. 19 1 109 117 22011753 10.1097/gme.0b013e31821f92df
2. C Ibe JA Simon 2010 Vulvovaginal atrophy: current and future therapies J Sex Med. 7 3 1042 1050 20500443 10.1111/j.1743-6109.2009.01692.x
3. R Burich M Degregorio 2011 Current treatment options for vulvovaginal atrophy Expert Rev Obstet Gynecol. 6 2 141 151 10.1586/eog.11.3
4. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol Epub. 2012.
5. S Palacios 2011 Selective estrogen receptor modulators: the future in menopausal treatment Minerva Ginecol. 63 3 275 286 21654612 1:STN:280: DC%2BC3MrovVShtg%3D%3D
6. JV Pinkerton SR Goldstein 2010 Endometrial safety: a key hurdle for selective estrogen receptor modulators in development Menopause. 17 3 642 653 20107426
7. US FDA. FDA approves Osphena for postmenopausal women experiencing pain during sex (media release). 26 Feb 2013. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm341128.htm.
8. TM (ospemifene) oral tablets: US prescribing information. Feb 2013. http://www.shionogi.com/pdf/PI/Osphena-PI. pdf. Accessed 12 Mar 2013.
9. GA Bachmann JO Komi The Ospemifene Study Group 2010 Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study Menopause. 17 3 480 486 20032798
10. Portman DJ, Bachmann GA, Simon JA, et al. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause Epub. 2013.
11. J Simon G Bachmann S Goldstein, et al. 2011 Evaluation of the safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women Climacteric. 14 89
12. JA Simon 2012 Efficacy and safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women (abstract) Menopause. 19 12 1397 1398
13. Shionogi Inc. US Food and Drug Administration accepts Shionogi's ospemifene New Drug Application in vulvar and vaginal atrophy (media release). 27 Jun 2012. http://www.shionogi.com.
14. Shionogi Inc. Pipeline. Feb 2013. http://www.shionogi.co.jp/company-en/ development/study/e-kaihatsu.pdf. Accessed 15 Mar 2013.
15. J Komi J Heikkinen EM Rutanen, et al. 2004 Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women Gynecol Endocrinol. 18 3 152 158 15255284 10.1080/09513590410001672197 1:CAS:528:DC%2BD2cXnslWku7c%3D
16. J Komi KS Lankinen M DeGregorio, et al. 2006 Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women J Bone Miner Metab. 24 4 314 318 16816926 10.1007/s00774-006-0689-9 1:CAS:528:DC%2BD28XmsVShtro%3D
17. E-M Rutanen J Heikkinen K Halonen, et al. 2003 Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial Menopause. 10 5 433 439 14501605 10.1097/01.GME.0000063609.62485.27
18. SK Voipio J Komi L Kangas, et al. 2002 Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women Maturitas. 43 3 207 214 12443837 10.1016/S0378-5122(02) 00206-2 1:CAS:528:DC%2BD38Xoslansrs%3D
19. J Komi KS Lankinen P Harkonen, et al. 2005 Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women Menopause. 12 2 202 209 15772568 10.1097/00042192- 200512020-00015
20. QuatRx Pharmaceuticals. QuatRx Pharmaceuticals announces merger with Hormos Medical (media release). 16 May 2005. http://www.quatrx.com.
21. QuatRx Pharmaceuticals Company. Shionogi enters into exclusive license agreement with QuatRx Pharmaceuticals to market ospemifene (media release). 2 Mar 2010. http://www.quatrx.com.
22. JL McCall MW DeGregorio 2010 Pharmacologic evaluation of ospemifene Expert Opin Drug Metab Toxicol. 6 6 773 779 20429673 10.1517/17425255.2010. 487483 1:CAS:528:DC%2BC3cXmtVGjtL0%3D
23. Q Qu H Zheng J Dahllund, et al. 2000 Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats Endocrinology. 141 2 809 820 10650964 10.1210/en.141.2.809 1:CAS:528:DC%2BD3cXmvFCrug%3D%3D
24. L Gennari D Merlotti F Valleggi, et al. 2007 Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development Drugs Aging. 24 5 361 379 17503894 10.2165/00002512-200724050-00002 1:CAS:528:DC%2BD2sXot1GjsbY%3D
25. GT Wurz KC Read C Marchisano-Karpman, et al. 2005 Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice J Steroid Biochem Mol Biol. 97 3 230 240 16153821 10.1016/j.jsbmb.2005.06.027 1:CAS:528:DC%2BD2MXht1Srtb7P
26. TL Taras GT Wurz MW DeGregorio 2001 In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer J Steroid Biochem Mol Biol. 77 4-5 271 279 11457665 10.1016/S0960-0760(01)00066-8 1:CAS:528:DC%2BD3MXlt1SltLg%3D
27. RA Burich NR Mehta GT Wurz, et al. 2012 Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model Menopause. 19 1 96 103 21926925 10.1097/gme. 0b013e318223e82a
28. U Hellmann-Blumberg TL Taras GT Wurz, et al. 2000 Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene Breast Cancer Res Treat. 60 1 63 70 10845810 10.1023/A:1006311214152 1:CAS:528:DC%2BD3cXktlSrs7o%3D
29. GT Wurz U Hellmann-Blumberg MW DeGregorio 2008 Pharmacologic effects of ospemifene in rhesus macaques: a pilot study Basic Clin Pharmacol Toxicol. 102 6 552 558 18346046 10.1111/j.1742-7843.2008.00235.x 1:CAS:528: DC%2BD1cXntFWmsLo%3D
30. H Zheng L Kangas PL Harkonen 2004 Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus J Steroid Biochem Mol Biol. 88 2 143 156 15084346 10.1016/j.jsbmb.2003.11.009 1:CAS:528:DC%2BD2cXjtVOitLw%3D
31. Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause Epub. 2012.
32. G Bachmann S Goldstein V Lin, et al. 2011 Efficacy of ospemifene when used in the treatment of vulvar and vaginal atrophy for up to 52 weeks in postmenopausal women (abstract) Climacteric. 14 92 10.3109/13697137.2010.491924
33. H Michael PL Harkonen L Kangas, et al. 2007 Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro Br J Pharmacol. 151 3 384 395 17420779 10.1038/sj.bjp.0707232 1:CAS:528:DC%2BD2sXlslCqtbY%3D
34. A Kallio T Guo E Lamminen, et al. 2008 Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells Mol Cell Endocrinol. 289 1-2 38 48 18455292 10.1016/j.mce.2008.03.005 1:CAS:528:DC%2BD1cXnsFKrt7o%3D
35. O Ylikorkala B Cacciatore K Halonen, et al. 2003 Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women Menopause. 10 5 440 447 14501606 10.1097/01.GME.0000063566.84134.98
36. GT Wurz LH Soe MW DeGregorio 2013 Ospemifene, vulvovaginal atrophy, and breast cancer Maturitas. 74 3 220 225 10.1016/j.maturitas.2012.12.002 1:CAS:528:DC%2BC3sXovVygtQ%3D%3D
37. MW DeGregorio GT Wurz TL Taras, et al. 2000 Pharmacokinetics of (deaminohydroxy) toremifene in humans: a new, selective estrogen-receptor modulator Eur J Clin Pharmacol. 56 6-7 469 475 11049009 10.1007/s002280000176 1:CAS:528:DC%2BD3cXmtlCmtbY%3D
38. S Bryson K Cornelissen M Anttila 2005 Absorption, metabolism, and excretion of ((3)H)-ospemifene following a single oral dose to postmenopausal women Clin Pharmacol Ther. 77 82 10.1016/j.clpt.2004.12.205
39. D Portman J Komi 2009 Long-term effects of ospemifene on the clinical signs of vaginal atrophy (abstract no. P-42) Menopause. 16 6 1252
40. S Goldstein G Bachmann V Lin, et al. 2011 Endometrial safety profile of ospemifene 60 mg when used for long-term treatment of vulvar and vaginal atrophy for up to 1 year Climacteric. 14 77